Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

DOPASCAN Injection ([{sup 123}I]{beta}-CIT): A radiopharmaceutical with potential for the diagnosis of Parkinson's disease

Journal Article · · AIP Conference Proceedings
DOI:https://doi.org/10.1063/1.59301· OSTI ID:21208098
 [1]
  1. Guilford Pharmaceuticals Inc., 6611 Tributary Street, Baltimore, Maryland 21224 (United States)
In conjunction with single photon emission computerized tomography (SPECT), the radiopharmaceutical [{sup 123}I]{beta}-CIT (DOPASCAN Injection) has demonstrated significant potential for the early diagnosis and monitoring of Parkinson's Disease. Well over 2000 patients worldwide have been studied with this product, which has completed phase II clinical studies. This review summarizes the development and clinical application of this new radiopharmaceutical product.
OSTI ID:
21208098
Journal Information:
AIP Conference Proceedings, Journal Name: AIP Conference Proceedings Journal Issue: 1 Vol. 475; ISSN APCPCS; ISSN 0094-243X
Country of Publication:
United States
Language:
English

Similar Records

Differential diagnosis of bilateral parietal abnormalities in I-123 IMP SPECT imaging
Journal Article · Sat Dec 01 04:00:00 UTC 1990 · Clinical Nuclear Medicine; (USA) · OSTI ID:6059670

SPECT brain imaging of the dopaminergic system in Parkinsonism using {sup 123}I and {sup 99m}Tc labeled agents
Journal Article · Wed Dec 01 04:00:00 UTC 2004 · Medical Physics · OSTI ID:20634545

Parametrization of textural patterns in {sup 123}I-ioflupane imaging for the automatic detection of Parkinsonism
Journal Article · Wed Jan 15 04:00:00 UTC 2014 · Medical Physics · OSTI ID:22251245